Research conducted by the Tufts Center for the Study of Drug Development (CSDD) found that protocol complexity correlates with longer clinical study times and poorer patient recruitment. Therefore, drug development companies are working to increase clinical trial...
The frequency of dual enrollment, in which participants enroll in multiple clinical trials at the same time in order to benefit from increased healthcare or payments, is up for debate among the Association of Clinical Research Organizations (ACRO) and industry...
A new report from PricewaterhouseCoopers (PwC) found that the use of a risk-based algorithm to monitor clinical studies reduced the deployment of research associates and targeted more high-risk patients and sites. Although CROs and sponsors have been hesitant to use...
inVentiv Health Clinical recently invested in Mytrus, a California based “Virtual Trial” company. Mytrus has previously parted with Pfizer to create REMOTE, an “at home” clinical study of the bladder control drug, Detrol LA. Although the Pfizer study failed to meet...
In 2012, an all-time high of 28,000 principal investigators participated in FDA regulated research, according to a study in the March/April Tufts Center for the Study of Drug Development (CSDD) Impact Report. However, compound annual growth in the number of active...
A recent study, “Oncology Clinical Trials: Drug Development and Case Studies” examined the average number of patients per site during different phases of oncology trials. The study found that Phase 1 trials averaged 12.9 patients per site, while Phase 2 and Phase...